Peanut Allergy Market Set to Grow at a 16% CAGR During the Study Period (2020-2034) Owing to Current Usage of Epinephrine, Anticipated Usage of XOLAIR in Adults, PALFORZIA in Toddlers and Expected Entry of Viaskin Peanut Patches
LAS VEGAS, July 16, 2025 /PRNewswire/ -- DelveInsight's Peanut Allergy Market Insights report includes a comprehensive understanding of current treatment practices, peanut allergy emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].
Key Takeaways from the Peanut Allergy Market Report
According to DelveInsight's analysis, the market size for peanut allergy was found to be USD 400 million in the 7MM in 2024, and is expected to witness a drastic growth owing to increased usage of approved therapies, expected entry of novel emerging therapies, and a slight increase in diagnosis over time.
In 2024, the US reported approximately ˜5,129,500 prevalent cases of peanut allergy, yet only about 50% of affected individuals received treatment, highlighting a significant gap in patient care and therapy adoption.
PALFORZIA has seen limited uptake due to modest clinical benefits over standard peanut avoidance, with minimal impact on reducing allergic reactions
Following PALFORZIA's approval in the US, Roche and Novartis' XOLAIR was approved in early 2024, adding a new option to the food allergy treatment landscape, including peanut allergy.
Although XOLAIR could be a lucrative option for adult patients with minimal needle phobia, XOLAIR's high annual cost may pose a barrier to affordability and patient access, potentially hindering its broader adoption.
By 2034, among all the therapies, the highest revenue is expected to be generated by VIASKIN in the 7MM. Around 70% of treated patients choose desensitization, reflecting strong demand, creatinga clear opportunity for safer, easier alternatives like Viaskin to improve adoption and long-term protection
Based on DelveInsight's assessment in 2024, the 7MM had 9.8 million diagnosed prevalent cases of peanut allergy.
Mild-to-moderate peanut allergy contributed majorly t in 2024 within the 7MM. Our trend estimates suggest a consistent rise in these cases during the study period (2020–2034).
Leading peanut allergy companies developing emerging therapies, such as DBV Technologies, Novartis, Aravax, ALK-Abello, InnoUp Farma, Intrommune Therapeutics, and others, are developing novel peanut allergy drugs that can be available in the peanut allergy market in the coming years.
The promising peanut allergy therapies in the pipeline include Viaskin (DBV712) peanut patch, Remibrutinib (LOU064), PVX108 (AVX-201), Sublingual Immunotherapy (SLIT)-Tablet, INP20, INT301, and others.
Discover which therapies are expected to grab the peanut allergy therapeutics market share @ Peanut Allergy Market Report
Peanut Allergy Market Dynamics
The peanut allergy market dynamics are expected to change in the coming years. PALFORZIA, administered orally, offers a convenient and accessible treatment option compared to traditional SC, intradermal, and epicutaneous therapies, potentially enhancing patient adherence and reducing the burden on healthcare systems; desensitization has improved peanut allergy treatment by increasing the reaction threshold, helping prevent accidental anaphylaxis and offering meaningful protection for patients and families, while the adult peanut allergy market remains an untapped opportunity, with XOLAIR as the sole approved treatment and only remibrutinib under evaluation, highlighting significant potential for growth, especially as increasing investment and partnerships in the allergy treatment space accelerate the development of novel therapies.
Furthermore, potential therapies are being investigated for the treatment of peanut allergy, and it is safe to predict that the treatment space will significantly impact the peanut allergy market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the peanut allergy market in the 7MM.
However, several factors may impede the growth of the peanut allergy market. Notable weakness in the peanut allergy landscape is the slow uptake of PALFORZIA, underdiagnosis of mild patients, lack of approved treatment options for adult patients(except XOLAIR), with remibrutinib being the only drug currently under evaluation for the 18–55 age group. This is compounded by the limited number of active drugs in the pipeline, highlighting a gap in therapeutic innovation that restricts treatment options and hinders progress in addressing diverse patient needs.
Additionally, the high annual cost of XOLAIR, ranging from USD 30,000 to USD 60,000, poses a significant threat by limiting affordability and access, thereby challenging its widespread adoption. Furthermore, inconsistent or unclear food labeling practices increase the risk of accidental exposure, complicating condition management and posing ongoing risks for individuals with peanut allergies.
Moreover, peanut allergy treatment poses a significant economic burden and disrupts patients' overall well-being and QOL. Furthermore, the peanut allergy market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the peanut allergy market growth.
Peanut Allergy Treatment Market
Managing peanut allergies requires a comprehensive approach, with strict avoidance of the allergen remaining the key method for preventing severe, potentially fatal anaphylactic reactions. However, recent clinical guidelines mark a significant change in prevention strategies by recommending the early introduction of peanut-containing foods between 4 to 6 months of age, even for infants at high risk. This proactive approach has been shown to greatly reduce the chances of developing a peanut allergy, replacing the older practice of strict avoidance.
While medications such as antihistamines, corticosteroids, and bronchodilators can be used during allergic reactions, it's important to note that they do not treat anaphylaxis directly. These are supportive treatments used alongside other interventions in managing anaphylactic episodes. Although allergen avoidance remains the foundation of care, innovative preventive measures are under development. One such method, oral immunotherapy, involves gradually increasing exposure to small amounts of peanut, and clinical trials have shown encouraging results.
Another promising desensitization technique is epicutaneous immunotherapy, where peanut protein is applied to the skin over time to help build tolerance. This form of therapy has improved peanut allergy management by increasing the reaction threshold, lowering the risk of accidental exposure, and providing patients with added protection and confidence.
Currently, PALFORZIA and XOLAIR are the only approved treatments for peanut allergy. PALFORZIA is authorized for children aged 1–3 and 4–17 years, while XOLAIR is approved for individuals aged 1 year and older. These peanut allergy therapies offer valuable options for both patients and healthcare professionals in managing peanut allergies.
To know more about peanut allergy treatment options, visit @ Peanut Allergy Medication
Peanut Allergy Pipeline Therapies and Key Companies
A robust pipeline of emerging therapies for peanut allergy is progressing, driven by innovative treatments with diverse mechanisms of action, such as Remibrutinib (Novartis), INP20 (InnoUp Farma), SLIT tablet (ALK-Abello), INT301 (Intrommune Therapeutics), and the combination of Linvoseltamab and Dupilumab. Among these, the Viaskin Peanut Patch (DBV Technologies) stands out as a promising noninvasive option, offering ease of use and a strong safety profile, which may make it especially suitable for young children aged 1 to 7.
Viaskin Peanut is an epicutaneous immunotherapy (EPIT) that delivers trace amounts of peanut protein via a skin patch to promote desensitization in allergic individuals. It has received both Fast Track and Breakthrough Therapy Designations from the US FDA. The therapy is currently being assessed in a Phase III clinical trial involving peanut-allergic children aged 4 to 7. DBV Technologies expects to share top-line data from the VITESSE trial (NCT05741476) in Q4 2025.
In March 2025, DBV Technologies and the FDA aligned on key regulatory steps following written responses to a Type D IND meeting request. The FDA agreed that safety exposure data from the VITESSE Phase III trial in children aged 4–7 would be adequate to support a Biologics License Application (BLA) for this age group, potentially advancing the BLA submission to the first half of 2026. A separate BLA for children aged 1–3 is planned for the second half of 2026, contingent on the successful outcome of the COMFORT Toddlers Study.
PVX108 is a next-generation immunotherapy that utilizes engineered peptides to specifically engage T cells and retrain the immune system, aiming to reverse allergic responses. It is currently in a Phase II clinical trial for children and adolescents with peanut allergies. In November 2024, Aravax established a UK subsidiary at Oxford Science Park, marking a strategic step in its global expansion in food allergy treatment. Additionally, in October 2024, the company completed patient enrollment for its Phase II study (AVX-201) evaluating PVX108.
Remibrutinib is an oral, highly selective, covalent Bruton's Tyrosine Kinase (BTK) inhibitor being developed for a range of autoimmune and inflammatory conditions, including chronic spontaneous urticaria, myasthenia gravis, multiple sclerosis, food allergy, and hidradenitis suppurativa. It is currently in a Phase II clinical trial for adults with peanut allergy.
These new peanut allergy therapies, which act on different molecular targets and pathways, represent encouraging alternatives to existing treatments. Their development underscores a growing emphasis on more precise and targeted strategies for managing the complexities of peanut allergy
Additionally, the anticipated launch of these emerging therapies are poised to transform the peanut allergy market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the peanut allergy market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about peanut allergy drugs in development @ Peanut Allergy Clinical Trials
Recent Developments in the Peanut Allergy Market
In March 2025, DBV Technologies reached an understanding with the US FDA based on written replies to its Type D IND meeting request. The FDA concurred with DBV's proposal that safety exposure data from the VITESSE Phase III study of the Viaskin Peanut Patch in children aged 4–7 years would be sufficient to support BLA filing for this age group, thereby accelerating the anticipated timeline for BLA submission to the first half of 2026.
In March 2025, the US FDA approved OMLYCLO (omalizumab-igec) as the first interchangeable biosimilar for reference XOLAIR and the first respiratory biosimilar for the treatment of moderate-to-severe persistent asthma, Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), IgE-mediated food allergy, and Chronic Spontaneous Urticaria (CSU).
In March 2025, DBV Technologies announced a financing of up to USD 306.9 million (EUR 284.5 million), comprising gross proceeds of USD 125.5 million (EUR 116.3 million) to be received upon closing and up to an additional USD 181.4 million (EUR 168.2 million) in gross proceeds contingent upon the full exercise of warrants, subject to the satisfaction of specified conditions.
In February 2025, Stallergenes Greer launched PALFORZIA in the US to treat toddler patients, ages 1–3 years, with a confirmed diagnosis of peanut allergy. The FDA approved the expanded indication for toddler patients (ages 1–3 years) in July 2024 based on the data from the Phase III POSEIDON (Peanut Oral Immunotherapy Study of Early Intervention for Desensitization) study that was published in the New England Journal of Medicine Evidence in 2023.
In January 2025, the European Commission approved the extension of the indication of PALFORZIA for the treatment of toddlers (ages 1–3) with a confirmed diagnosis of peanut allergy. The marketing authorization covered all 27 European member states and the three European Economic Area states (Iceland, Liechtenstein, and Norway).
In December 2024, ALK announced positive interim results from the Phase I/II clinical trial (ALLIANCE) for its investigational SLIT tablet for the treatment of peanut allergy.
Peanut Allergy Overview
Peanut allergy is one of the most prevalent food allergies in children and has notably increased over recent decades. It results from an abnormal immune response involving IgE antibodies directed against peanut proteins, which can cause severe and potentially life-threatening anaphylactic reactions. Beyond the immediate health dangers, this allergy significantly affects the quality of life for both patients and their families.
Compared to other IgE-mediated food allergies, peanut allergy is associated with a higher incidence of anaphylaxis-related fatalities in emergencies. In individuals with this allergy, the initial exposure to peanut antigens activates Th2 cells that release cytokines, encouraging the production of IgE antibodies. These antibodies attach to Fce receptors on mast cells and basophils, sensitizing them.
Upon subsequent exposure, the allergen crosslinks the IgE on these primed cells, leading to degranulation and the release of inflammatory mediators such as histamine, leukotrienes, and cytokines. This response triggers vasodilation, increased vascular permeability, and inflammation, manifesting in allergic symptoms.
In addition to these biochemical processes, mechanical factors in the allergic microenvironment also influence immune activity. When diagnosing peanut and other food allergies, a detailed clinical history is essential to appropriately interpret test results. The most accurate diagnostic method is the double-blind, placebo-controlled food challenge (DBPCFC). However, skin prick testing (SPT) and measurement of specific IgE levels are commonly used first-line tools due to their speed and affordability.
Peanut Allergy Epidemiology Segmentation
The peanut allergy epidemiology section provides insights into the historical and current peanut allergy patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.
The peanut allergy market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
Total Diagnosed Prevalent Cases of Peanut Allergy
Gender-specific Cases of Peanut Allergy
Age-specific Cases of Peanut Allergy
Severity-specific Cases of Peanut Allergy
Peanut Allergy Market Report Metrics
Details
Study Period
2020–2034
Coverage
7MM [The United States, the EU4 (Germany, France, Italy, and Spain) and The United Kingdom, and Japan].
Peanut Allergy Market CAGR
16 %
Peanut Allergy Market Size in 2024
USD 400 Million
Key Peanut Allergy Companies
DBV Technologies, Novartis, Aravax, ALK-Abello, InnoUp Farma, Intrommune Therapeutics, Stallergenes Greer, Roche, and others
Key Peanut Allergy Therapies
Viaskin (DBV712) peanut patch, Remibrutinib (LOU064), PVX108 (AVX-201), Sublingual Immunotherapy (SLIT)-Tablet, INP20, INT301, PALFORZIA, XOLAIR, and others
Scope of the Peanut Allergy Market Report
Therapeutic Assessment: Peanut Allergy current marketed and emerging therapies
Peanut Allergy Market Dynamics: Key Market Forecast Assumptions of Emerging Peanut Allergy Drugs and Market Outlook
Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
Unmet Needs, KOL's views, Analyst's views, Peanut Allergy Market Access and Reimbursement
Download the report to understand which factors are driving peanut allergy market trends @ Peanut Allergy Treatment Market
Table of Contents
1
Key Insights
2
Report Introduction
3
Executive Summary
4
Key Events
5
Epidemiology and Market Forecast Methodology
6
Peanut Allergy Market Overview at a Glance
6.1
Market Share (%) Distribution by Therapies in 2024 in the 7MM
6.2
Market Share (%) Distribution by Therapies in 2034 in the 7MM
7
Disease Background and Overview
7.1
Introduction
7.2
Symptoms
7.3
Risk Factors
7.4
Pathophysiology of Peanut Allergy
7.5
Diagnosis
7.6
Treatment
8
Epidemiology and Patient Population
8.1
Key Findings
8.2
Assumptions and Rationale: 7MM
8.3
Total Diagnosed Prevalent Cases of Peanut Allergy in the 7MM
8.4
The United States
8.5
EU4 and the UK
8.6
Japan
9
Patient Journey
10
Marketed Drugs
10.1
Key Competitors
10.2
PALFORZIA (peanut allergen powder-dnfp): Stallergenes Greer
10.3
XOLAIR (omalizumab): Roche and Novartis
11
Emerging Therapies
11.1
Key Cross Competition
11.2
Viaskin (DBV712) peanut patch: DBV Technologies
11.3
Remibrutinib (LOU064): Novartis
11.4
PVX108 (AVX-201): Aravax
11.5
Sublingual Immunotherapy (SLIT)-Tablet: ALK-Abello
12
Peanut Allergy: Seven Major Market Analysis
12.2
Market Outlook
12.3
Conjoint Analysis
12.4
Key Market Forecast Assumptions
12.5
DBV Technology: In-depth Analysis
12.6
Total Market Size of Peanut Allergy by Country in the 7MM
12.7
United States Market Size
12.8
EU4 and the UK Market Size
12.9
Japan Market Size
13
Unmet Needs
14
SWOT Analysis
15
KOL Views
16
Market Access and Reimbursement
16.1
United States
16.2
EU4 and the UK
16.3
Japan
16.4
Market Access and Reimbursement of Peanut Allergy
17
Bibliography
18
Report Methodology
Related Reports
Food Allergy Market
Food Allergy Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key food allergy companies including Stallergenes Greer, Roche, Novartis, ARS Pharmaceuticals, ALK-Abelló, Alfresa Pharma, DBV Technologies, Aquestive Therapeutics, Bryn Pharma, Aravax, RAPT Therapeutics, Allergy Therapeutics, Regeneron Pharmaceuticals, among others.
Peanut Allergy Pipeline
Peanut Allergy Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key peanut allergy companies, including Allergy Therapeutics, DBV Technologies, Novartis, Aravax, ALK-Abello, Intrommune Therapeutics, LAPIX Therapeutics, among others.
Food Allergy Pipeline
Food Allergy Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key food allergy companies, including DBV Technologies, Aravax, Xencor, Novartis AG, Vedanta Biosciences, Alladapt Immunotherapeutics, Intrommune Therapeutics, IgGenix, Lapix Therapeutics, Neovacs, Inimmune, among others.
Lactose Intolerance Market
Lactose Intolerance Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key lactose intolerance companies including CRitter Pharmaceuticals Inc., a2 Milk Company Ltd, VenterPharma, Eurofarma Laboratorios S.A, among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact UsShruti Thakurinfo@delveinsight.com +14699457679www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/peanut-allergy-market-set-to-grow-at-a-16-cagr-during-the-study-period-20202034-owing-to-current-usage-of-epinephrine-anticipated-usage-of-xolair-in-adults-palforzia-in-toddlers-and-expected-entry-of-viaskin-peanut-patches--302506490.html
SOURCE DelveInsight Business Research, LLP
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
43 minutes ago
- Yahoo
Here's How You Can Earn $100 In Passive Income By Investing In Healthpeak Properties Stock
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Healthpeak Properties Inc. (NYSE:DOC) is a real estate investment trust that owns, operates, and develops high-quality real estate focused on healthcare discovery and delivery. It will report its Q3 2025 earnings on Oct. 23. Wall Street analysts expect the company to post EPS of $0.22, down from $0.45 in the prior-year period. According to data from Benzinga Pro, quarterly revenue is expected to be $700.87 million, up from $700.40 million a year earlier. Don't Miss: Would you have invested in eBay or Uber early? The same backers are betting on . 'Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. The 52-week range of Healthpeak Properties stock price was $16.63 to $23.26. Healthpeak Properties' dividend yield is 7.12%. It paid $1.22 per share in dividends during the last 12 months. The Latest On Healthpeak Properties The company on July 24 announced its Q2 2025 earnings, posting FFO of $0.46, compared to the consensus estimate of $0.47, and revenues of $694.35 million, compared ot the consensus of $699.17 million, as reported by Benzinga. The company provided its full-year 2025 guidance, expecting diluted FFO per share in the range of $1.81 to $1.87, and diluted EPS of $0.25 to $0.31. Trending: If there was a new fund backed by Jeff Bezos offering a ? Check out this article by Benzinga for four analysts' insights on Healthpeak Properties. How Can You Earn $100 Per Month As A Healthpeak Properties Investor? If you want to make $100 per month — $1,200 annually — from Healthpeak Properties dividends, your investment value needs to be approximately $16,854, which is around 983 shares at $17.14 each. Understanding the dividend yield calculations: When making an estimate, you need two key variables — the desired annual income ($1,200) and the dividend yield (7.12% in this case). So, $1,200 / 0.0712 = $16,854 to generate an income of $100 per month. You can calculate the dividend yield by dividing the annual dividend payments by the current price of the dividend yield can change over time. This is the outcome of fluctuating stock prices and dividend payments on a rolling basis. For instance, assume a stock that pays $2 as an annual dividend is priced at $50. Its dividend yield would be $2/$50 = 4%. If the stock price rises to $60, the dividend yield drops to 3.33% ($2/$60). A drop in stock price to $40 will have an inverse effect and increase the dividend yield to 5% ($2/$40). In summary, income-focused investors may find Healthpeak Properties stock an attractive option for making a steady income of $100 per month by owning 983 shares of stock. Read Next: Kevin O'Leary Says Real Estate's Been a Smart Bet for 200 Years — Image: Shutterstock This article Here's How You Can Earn $100 In Passive Income By Investing In Healthpeak Properties Stock originally appeared on
Yahoo
an hour ago
- Yahoo
Get the Samsung Galaxy Ring for $100 off
Smartwatches get all the attention, but smart rings are a great alternative if you're looking for a more subtle way to track your health and fitness metrics. While there are plenty to choose from, the Samsung Galaxy Ring is going to be a top choice for Android and Samsung device owners, especially since you won't need to pay any additional monthly fees to use it. And right now, you can score the ring for $100 below its retail price as Samsung, Best Buy, and Amazon all have it on sale. Ditch the bulky watch and get this instead While it's been a year since the release of the Galaxy Ring, it's still a very capable wearable. You get a simple yet pleasing design, with lots of different colors, and excellent health tracking features. The battery is also quite good, lasting a full week, and it even comes with a case that can recharge the ring when you can't plug in. Now, since the ring doesn't have a screen, you'll need to install the Samsung Health app in order to get all the details. This is where you'll be able to see the details of your day, from health rate tracking, blood oxygen levels, sleep tracking, and more. Perhaps the only area where the watch falls short is that it can only track a small number of activities. This isn't going to be a problem for most people, but if you're looking for something a bit more aggressive on the fitness side, you'll have to look elsewhere. Perhaps the best part about all of this is that you won't need any kind of membership in order to access all the data like some of the competition. Overall, it's a fantastic smart ring to own, and especially now that it's $100 less. It can do pretty much everything a smartwatch does but offers it in a much smaller package. It's easy to wear and is durable enough to handle most of the things you throw at it. Plus, this is one of the best discounts we've seen, making it a great time to buy.
Yahoo
2 hours ago
- Yahoo
Most People Don't Realize This Common Daily Habit Is Spiking Their Blood Pressure
Most People Don't Realize This Common Daily Habit Is Spiking Their Blood Pressure originally appeared on Parade. If you have high blood pressure (or it runs in your family), you've likely talked with your doctor about the best ways to keep it in check. You know tobacco use is completely out of the question (as it should be for everyone anyway), to go easy on foods like bacon, sausage, French fries and donuts) and the importance of regular exercise. But another important part of managing blood pressure is stress management. Experiencing stress is inevitable (according to The Institute of Stress, 43% of adults reported feeling more anxious in 2024 than they did in 2023), but how you deal with it is within your according to cardiologists we talked to, there's one common habit in particular that is a constant source of stress, but it's become so normalized that many people don't even realize it.🩺SIGN UP for tips to stay healthy & fit with the top moves, clean eats, health trends & more delivered right to your inbox twice a week💊 The Surprising Daily Habit That Raises Blood Pressure How often do you check your email? According to statistics compiled by Email Tool Tester, 61% of people check their email on their phone, which means it's accessible any time of the day. This is often a habit that's done continuously, from the moment we wake up (fifty-eight percent of people check their email first thing in the morning) until the moment we go to Aye Thandar Win, MD, FACC, a cardiologist with Banner Health, explains that constantly checking your email can lead to living in a state of fight-or-flight without you even realizing it—and that's bad news for your heart. 'In today's hyper-connected world, email has become a constant companion—and for many, a source of relentless stress," she says. "The ping of a new message can trigger a cascade of anxiety, especially for those who feel compelled to check their inbox obsessively, even late at night. Each time you check your inbox, your body may release stress hormones like cortisol and adrenaline. These hormones prepare you for a 'fight or flight' response, temporarily increasing heart rate and blood pressure." Related: Dr. Mona Shah, MD, who is board-certified in cardiology and holistic medicine, echoes that checking email throughout the day can lead to a constant stream of cortisol and adrenaline that is hazardous to health long-term. 'Cortisol creates increased inflammation, weight gain and worsens our immune response. Adrenaline streaming throughout our bodies can increase blood pressure, cause platelets to be stickier which can cause clotting in our arteries and increase the stiffness and constriction in our arteries,' she says. Dr. Shah adds that both cortisol and adrenaline from increased stress can even affect DNA and accelerate aging. 'Stiffened arteries, sticky platelets, inflammation and higher blood pressure all are linked to increased heart attacks and coronary artery disease,' she emphasizes. One indication that your emails are stressing you out without you even realizing it is a change in your breathing. Dr. Win explains that often when someone is anxiously scrolling their emails, their breathing will become shallow; an unconscious switch many people don't even realize is happening. 'This pattern, unlike deep and steady breaths, reduces oxygen intake and keeps the body in a heightened state of alert. Over the long term, habitual shallow breathing can subtly but significantly impact heart health,' she says. Related: Dr. Win explains that shallow breathing negatively impacts heart health in several ways, including reducing oxygen delivery, keeping the body in a stress-response mode (which elevates blood pressure) and releasing cortisol and adrenaline, which, as previously mentioned, can harm blood vessels and heart function. If you check your email before going to bed, both doctors say this could make it harder to fall asleep—and getting consistently good sleep is essential for healthy blood pressure and heart health. 'Sleeping less than six hours a day can increase heart disease risk by almost 20%!' Dr. Shah emphasizes. Related: How To Stop Compulsively Checking Your Email It's important to manage both major sources of stress as well as micro sources of stress, like emails. 'I have seen time and time again chronic stress take a major toll on overall health, specifically heart disease risk and an increase in heart attacks,' Dr. Shah break the cycle of constantly checking your email, Dr. Win recommends setting boundaries, designating certain times of the day for checking email and not checking it outside of those windows. To avoid checking it compulsively, she recommends turning off your Throughout the day, Dr. Win says to check in with yourself, noticing your breathing. If you notice that you're taking shallow breaths instead of deep, full ones, take a few deep breaths. 'Try diaphragmatic breathing—slow, deep breaths through your nose, expanding your belly—for five to 10 minutes daily. This calms the nervous system, lowers heart rate and improves oxygen flow,' she like how the stress from constantly checking your email negatively impacts heart health, Dr. Shah explains that taking actionable steps to reduce stress benefits heart health, including blood pressure. She explains that the relaxation response causes 'happy' hormones serotonin, oxytocin and dopamine to be released. When this happens, she says that the arteries are relaxed and dilated, blood pressure lowers and inflammation lowers. 'We need to make the choices for ourselves to have a healthy sustainable future and longevity. Unfortunately, no one is going to say 'put the phone down' or 'close the laptop.' Have non-negotiables with yourself that after a certain amount of time or emails you are shutting it down, remembering your heart is at risk,' Dr. Shah says. No email is worth sacrificing your health over. Up Next:Sources Dr. Aye Thandar Win, MD, FACC, cardiologist with Banner Health Dr. Mona Shah, MD, cardiologist Most People Don't Realize This Common Daily Habit Is Spiking Their Blood Pressure first appeared on Parade on Aug 16, 2025 This story was originally reported by Parade on Aug 16, 2025, where it first appeared.
